These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 36102236)

  • 1. Time-Dependent Risk of Cardiovascular Events Following an Exacerbation in Patients With Chronic Obstructive Pulmonary Disease: Post Hoc Analysis From the IMPACT Trial.
    Dransfield MT; Criner GJ; Halpin DMG; Han MK; Hartley B; Kalhan R; Lange P; Lipson DA; Martinez FJ; Midwinter D; Singh D; Wise R; Kunisaki KM
    J Am Heart Assoc; 2022 Sep; 11(18):e024350. PubMed ID: 36102236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased Risk of Severe Cardiovascular Events Following Exacerbations of Chronic Obstructive Pulmonary Disease: Results of the EXACOS-CV Study in Japan.
    Matsunaga K; Yoshida Y; Makita N; Nishida K; Rhodes K; Nordon C
    Adv Ther; 2024 Aug; 41(8):3362-3377. PubMed ID: 38976123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temporal Risk of Nonfatal Cardiovascular Events After Chronic Obstructive Pulmonary Disease Exacerbation: A Population-based Study.
    Graul EL; Nordon C; Rhodes K; Marshall J; Menon S; Kallis C; Ioannides AE; Whittaker HR; Peters NS; Quint JK
    Am J Respir Crit Care Med; 2024 Apr; 209(8):960-972. PubMed ID: 38127850
    [No Abstract]   [Full Text] [Related]  

  • 4. Risk of cardiovascular events after an exacerbation of chronic obstructive pulmonary disease: results from the EXACOS-CV cohort study using the PHARMO Data Network in the Netherlands.
    Swart KMA; Baak BN; Lemmens L; Penning-van Beest FJA; Bengtsson C; Lobier M; Hoti F; Vojinovic D; van Burk L; Rhodes K; Garbe E; Herings RMC; Nordon C; Simons SO
    Respir Res; 2023 Nov; 24(1):293. PubMed ID: 37990197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Impact of Exacerbation History on the Safety and Efficacy of Aclidinium in Patients with Chronic Obstructive Pulmonary Disease and Increased Cardiovascular Risk: ASCENT-COPD Trial.
    Wise RA; Chapman KR; Scirica BM; Daoud SZ; Lythgoe D; Garcia-Gil E
    Int J Chron Obstruct Pulmon Dis; 2021; 16():689-699. PubMed ID: 33776428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic Obstructive Pulmonary Disease Exacerbations Increase the Risk of Subsequent Cardiovascular Events: A Longitudinal Analysis of the COPDGene Study.
    Yang HM; Ryu MH; Carey VJ; Kinney GL; Hokanson JE; Dransfield MT; Hersh CP; Silverman EK;
    J Am Heart Assoc; 2024 Jun; 13(11):e033882. PubMed ID: 38818936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of Death and Cardiovascular Events Following an Exacerbation of COPD: The EXACOS-CV US Study.
    Daniels K; Lanes S; Tave A; Pollack MF; Mannino DM; Criner G; Neikirk A; Rhodes K; Feigler N; Nordon C
    Int J Chron Obstruct Pulmon Dis; 2024; 19():225-241. PubMed ID: 38259591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heightened long-term cardiovascular risks after exacerbation of chronic obstructive pulmonary disease.
    Hawkins NM; Nordon C; Rhodes K; Talukdar M; McMullen S; Ekwaru P; Pham T; Randhawa AK; Sin DD
    Heart; 2024 Apr; 110(10):702-709. PubMed ID: 38182279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exacerbations Predict Severe Cardiovascular Events in Patients with COPD and Stable Cardiovascular Disease-A Nationwide, Population-Based Cohort Study.
    Løkke A; Hilberg O; Lange P; Ibsen R; Telg G; Stratelis G; Lykkegaard J
    Int J Chron Obstruct Pulmon Dis; 2023; 18():419-429. PubMed ID: 37034899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis.
    Oba Y; Keeney E; Ghatehorde N; Dias S
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012620. PubMed ID: 30521694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of COPD exacerbations and acute cardiovascular events: a systematic review and meta-analysis.
    Müllerová H; Marshall J; de Nigris E; Varghese P; Pooley N; Embleton N; Nordon C; Marjenberg Z
    Ther Adv Respir Dis; 2022; 16():17534666221113647. PubMed ID: 35894441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study.
    Vogelmeier CF; Chapman KR; Miravitlles M; Roche N; Vestbo J; Thach C; Banerji D; Fogel R; Patalano F; Olsson P; Kostikas K; Wedzicha JA
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1125-1134. PubMed ID: 29692607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular events after exacerbations of chronic obstructive pulmonary disease: Results from the EXAcerbations of COPD and their OutcomeS in CardioVascular diseases study in Italy.
    Calabria S; Ronconi G; Dondi L; Dondi L; Dell'Anno I; Nordon C; Rhodes K; Rogliani P; Dentali F; Martini N; Maggioni AP
    Eur J Intern Med; 2024 Sep; 127():97-104. PubMed ID: 38729787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the SUMMIT Randomized Clinical Trial.
    Kunisaki KM; Dransfield MT; Anderson JA; Brook RD; Calverley PMA; Celli BR; Crim C; Hartley BF; Martinez FJ; Newby DE; Pragman AA; Vestbo J; Yates JC; Niewoehner DE;
    Am J Respir Crit Care Med; 2018 Jul; 198(1):51-57. PubMed ID: 29442524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LABA/LAMA fixed-dose combinations
    Chen CY; Chen WC; Huang CH; Hsiang YP; Sheu CC; Chen YC; Lin MC; Chu KA; Lee CH; Wei YF
    Ther Adv Respir Dis; 2020; 14():1753466620937194. PubMed ID: 32643547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seasonal and Regional Variations in Chronic Obstructive Pulmonary Disease Exacerbation Rates in Adults without Cardiovascular Risk Factors.
    So JY; Zhao H; Voelker H; Reed RM; Sin D; Marchetti N; Criner GJ
    Ann Am Thorac Soc; 2018 Nov; 15(11):1296-1303. PubMed ID: 30063372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial.
    Hanania NA; Mannino DM; Criner GJ; Dransfield MT; Han MK; Jones CE; Kilbride S; Lomas DA; Martin N; Martinez FJ; Singh D; Wise RA; Halpin DMG; Lima R; Lipson DA
    Chest; 2021 Mar; 159(3):985-995. PubMed ID: 33031829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elucidating the risk of cardiopulmonary consequences of an exacerbation of COPD: results of the EXACOS-CV study in Germany.
    Vogelmeier CF; Rhodes K; Garbe E; Abram M; Halbach M; Müllerová H; Kossack N; Timpel P; Kolb N; Nordon C
    BMJ Open Respir Res; 2024 Mar; 11(1):. PubMed ID: 38555102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study.
    Wedzicha JA; Singh D; Tsiligianni I; Jenkins C; Fucile S; Fogel R; Shen S; Goyal P; Mezzi K; Kostikas K
    Respir Res; 2019 Jan; 20(1):4. PubMed ID: 30621717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statins did not reduce the frequency of exacerbations in individuals with COPD and cardiovascular comorbidities in the COSYCONET cohort.
    Frantzi N; Nguyen XP; Herr C; Alter P; Söhler S; Soriano D; Watz H; Waschki B; Trinkmann F; Eichenlaub M; Trudzinski FC; Michels-Zetsche JD; Omlor A; Seiler F; Moneke I; Biertz F; Rohde G; Stolz D; Welte T; Kauczor HU; Kahnert K; Jörres RA; Vogelmeier CF; Bals R; Fähndrich S;
    Respir Res; 2024 May; 25(1):207. PubMed ID: 38750572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.